Top

International Orthopaedics

Published in:

01-03-2021 | Bone Tumor | Review Article

The impact of curettage technique on local control in giant cell tumour of bone

Authors: Gennady N. Machak, Andrey I. Snetkov

Published in: International Orthopaedics | Issue 3/2021

Abstract

Introduction

Although consensus has been reached regarding the main aspects of intralesional surgery for giant cell tumour of the bone (GCTB), debates continue about the most effective combination of local adjuvants. The purpose of study was to analyze the previous experience and determine the most effective curettage approach for GCTB.

Methods

We summarized the findings from 89 papers published from 1962 to 2020 related to this subject. Database consisted of 137 treated groups that included 6441 patients who underwent different curettage techniques without pre-operative administration of bisphosphonates or RANKL inhibitors.

Results

Recurrence rates after simple curettage ranged between 27 and 82% with a median value at 47%. The use of one or two local adjuvants reduced the incidence of recurrences approximately by 50% when compared with simple curettage. High-speed burring combined with chemical adjuvants or followed by poly(methyl methacrylate) cementation with or without bone grafting further improved the local control leading to good and excellent results; however, these were not documented in all studies. Simultaneous use of burring, chemical adjuvants, and cementation, which we named here as combined curettage, allowed to down local relapses to the range of 0–26%, with a median at 11%. Oncologic outcomes after combined curettage are significantly better when compared with simple curettage (p < 0.0001) and other variants of enhancement (p = 0.001).

Conclusions

Combined curettage appears to provide the most potent and comprehensive impact on residual tumour cells located in risk zones. This approach should be considered for locally advanced tumours when function-preserving surgery is planned. Additional comparative studies are required to define the optimal curettage enhancement for each individual patient.

Available only for authorised users

Klenke FM, Wenger DE, Inwards CY et al (2011) Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 469(2):591–599. https://doi.org/10.1007/s11999-010-1501-7CrossRefPubMed

Klenke FM, Wenger DE, Inwards CY et al (2011) Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res 469(4):1181–1187. https://doi.org/10.1007/s11999-010-1560-9CrossRefPubMed

Errani C, Tsukamoto S, Ciani G, Donati DM (2019) Present day controversies and consensus in curettage for giant cell tumor of bone. J Clin Orthop Trauma 10(6):1015–1020. https://doi.org/10.1016/j.jcot.2019.09.017CrossRefPubMedPubMedCentral

Knochentumoren A, Becker WT, Dohle J, Bernd L et al (2008) Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 90(5):1060–1067. https://doi.org/10.2106/JBJS.D.02771CrossRef

Blackley HR, Wunder JS, Davis AM et al (1999) Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 81(6):811–820. https://doi.org/10.2106/00004623-199906000-00008CrossRefPubMed

Turcotte RE, Wunder JS, Isler MH et al (2002) Giant cell tumor of long bone: a Canadian sarcoma group study. Clin Orthop Relat Res 397:248–258. https://doi.org/10.1097/00003086-200204000-00029CrossRef

Balke M, Schremper L, Gebert C et al (2008) Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 134(9):969–978. https://doi.org/10.1007/s00432-008-0370-xCrossRefPubMed

Prosser GH, Baloch KG, Tillman RM et al (2005) Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res 435:211–218. https://doi.org/10.1097/01.blo.0000160024.06739.ffCrossRef

Gaston CL, Bhumbra R, Watanuki M et al (2011) Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone? J Bone Joint Surg Br 93(12):1665–1669. https://doi.org/10.1302/0301-620X.93B12.27663CrossRefPubMed

10.

Kundu ZS, Gogna P, Singla R et al (2015) Joint salvage using sandwich technique for giant cell tumors around knee. J Knee Surg 28(2):157–164. https://doi.org/10.1055/s-0034-1373738CrossRefPubMed

11.

He H, Zeng H, Luo W et al (2019) Surgical treatment options for giant cell tumors of bone around the knee joint: extended curettage or segmental resection? Front Oncol 9:946. https://doi.org/10.3389/fonc.2019.00946CrossRefPubMedPubMedCentral

12.

Bickels J, Campanacci DA (2020) Local adjuvant substances following curettage of bone tumors. J Bone Joint Surg Am 102(2):164–174. https://doi.org/10.2106/JBJS.19.00470CrossRefPubMed

13.

Algawahmed H, Turcotte R, Farrokhyar F, Ghert M (2010) High-speed burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: a systematic review and meta-analysis. Sarcoma 10(2010):586090. https://doi.org/10.1155/2010/586090CrossRef

14.

Vaishya R, Pokhrel A, Agarwal AK, Vijay V (2019) Current status of bone cementing and bone grafting for giant cell tumour of bone: a systemic review. Ann R Coll Surg Engl 101(2):79–85. https://doi.org/10.1308/rcsann.2019.0004CrossRefPubMedPubMedCentral

15.

Campanacci M, Baldini N, Boriani S, Sudanese A (1987) Giant-cell tumor of bone. J Bone Joint Surg Am 69(1):106–114CrossRef

16.

Capanna R, Fabbri N, Bettelli G (1990) Curettage of giant cell tumor of bone. The effect of surgical technique and adjuvants on local recurrence rate. Chir Organi Mov 75(1 Suppl):206PubMed

17.

Kivioja AH, Blomqvist C, Hietaniemi K et al (2008) Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian sarcoma group study of 294 patients followed for a median time of 5 years. Acta Orthop 79(1):86–93. https://doi.org/10.1080/17453670710014815CrossRefPubMed

18.

Tang H, Moro A, Feng W et al (2019) Giant cell tumors combined with secondary aneurysmal bone cysts are more likely to develop postoperative recurrence: a retrospective study of 256 cases. J Surg Oncol 120(3):359–365. https://doi.org/10.1002/jso.25588CrossRefPubMed

19.

O'Donnell RJ, Springfield DS, Motwani HK et al (1994) Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 76(12):1827–1833. https://doi.org/10.2106/00004623-199412000-00009CrossRefPubMed

20.

Jones KB, DeYoung BR, Morcuende JA, Buckwalter JA (2006) Ethanol as a local adjuvant for giant cell tumor of bone. Iowa Orthop J 26:69–76PubMedPubMedCentral

21.

Niu X, Zhang Q, Hao L et al (2012) Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am 94(5):461–467. https://doi.org/10.2106/JBJS.J.01922CrossRefPubMed

22.

van der Heijden L, Dijkstra PD, van de Sande MA et al (2014) The clinical approach toward giant cell tumor of bone. Oncologist 19(5):550–561. https://doi.org/10.1634/theoncologist.2013-0432CrossRefPubMedPubMedCentral

23.

Hirn M, de Silva U, Sidharthan S et al (2009) Bone defects following curettage do not necessarily need augmentation. Acta Orthop 80(1):4–8. https://doi.org/10.1080/17453670902804505CrossRefPubMedPubMedCentral

24.

Jeys LM, Suneja R, Chami G et al (2006) Impending fractures in giant cell tumours of the distal femur: incidence and outcome. Int Orthop 30(2):135–138. https://doi.org/10.1007/s00264-005-0061-zCrossRefPubMedPubMedCentral

25.

Oda Y, Miura H, Tsuneyoshi M, Iwamoto Y (1998) Giant cell tumor of bone: oncological and functional results of long-term follow-up. Jpn J Clin Oncol 28(5):323–328. https://doi.org/10.1093/jjco/28.5.323CrossRefPubMed

26.

Pietschmann MF, Dietz RA, Utzschneider S et al (2010) The influence of adjuvants on local recurrence rate in giant cell tumour of the bone. Acta Chir Belg 110(6):584–589CrossRef

27.

Trieb K, Bitzan P, Lang S et al (2001) Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol 27(2):200–202. https://doi.org/10.1053/ejso.2000.1086CrossRefPubMed

28.

Bini SA, Gill K, Johnston JO (1995) Giant cell tumor of bone. Curettage and cement reconstruction. Clin Orthop Relat Res 321:245–250

29.

Ghert MA, Rizzo M, Harrelson JM, Scully SP (2002) Giant-cell tumor of the appendicular skeleton. Clin Orthop Relat Res 400:201–210. https://doi.org/10.1097/00003086-200207000-00025CrossRef

30.

Gross M, Mohan R (2002) The midterm results of giant cell tumours of bone treated by curettage, high speed burring and cementation. J Joint Bone Surgery Br 84-B(Suppl. III):207. https://doi.org/10.1302/0301-620X.84BSUPP_III.0840207dCrossRef

31.

Vult von Steyern F, Bauer HC, Trovik C et al (2006) Treatment of local recurrences of giant cell tumour in long bones after curettage and cementing. A Scandinavian sarcoma group study. J Bone Joint Surg Br 88(4):531–535. https://doi.org/10.1302/0301-620X.88B4.17407CrossRefPubMed

32.

Errani C, Ruggieri P, Asenzio MA et al (2010) Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 36(1):1–7. https://doi.org/10.1016/j.ctrv.2009.09.002CrossRefPubMed

33.

Gao ZH, Yin JQ, Xie XB et al (2014) Local control of giant cell tumors of the long bone after aggressive curettage with and without bone cement. BMC Musculoskelet Disord 15:330. https://doi.org/10.1186/1471-2474-15-330CrossRefPubMedPubMedCentral

34.

Benevenia J, Rivero SM, Moore J et al (2017) Supplemental bone grafting in giant cell tumor of the extremity reduces nononcologic complications. Clin Orthop Relat Res 475(3):776–783. https://doi.org/10.1007/s11999-016-4755-xCrossRefPubMed

35.

Errani C, Tsukamoto S, Leone G et al (2018) Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. J Bone Joint Surg Am 100(6):496–504. https://doi.org/10.2106/JBJS.17.00057CrossRefPubMed

36.

Gitelis S, Mallin BA, Piasecki P, Turner F (1993) Intralesional excision compared with en bloc resection for giant-cell tumors of bone. J Bone Joint Surg Am 75(11):1648–1655. https://doi.org/10.2106/00004623-199311000-00009CrossRefPubMed

37.

Lin WH, Lan TY, Chen CY et al (2011) Similar local control between phenol- and ethanol-treated giant cell tumors of bone. Clin Orthop Relat Res 469(11):3200–3208. https://doi.org/10.1007/s11999-011-1962-3CrossRefPubMedPubMedCentral

38.

Oh JH, Yoon PW, Lee SH et al (2006) Surgical treatment of giant cell tumour of long bone with anhydrous alcohol adjuvant. Int Orthop 30(6):490–494. https://doi.org/10.1007/s00264-006-0154-3CrossRefPubMedPubMedCentral

39.

Omlor GW, Lange J, Streit M et al (2019) Retrospective analysis of 51 intralesionally treated cases with progressed giant cell tumor of the bone: local adjuvant use of hydrogen peroxide reduces the risk for tumor recurrence. World J Surg Onc 17:73. https://doi.org/10.1186/s12957-019-1613-9CrossRef

40.

Persson BM, Ekelund L, Lövdahl R, Gunterberg B (1984) Favourable results of acrylic cementation for giant cell tumors. Acta Orthop Scand 55(2):209–214. https://doi.org/10.3109/17453678408992339CrossRefPubMed

41.

Wuisman P, Härle A, Nommensen B et al (1989) Der Riesenzell-tumor des Knochens. Eine analyse von 69 Fällen [Giant cell tumor of bone. An analysis of 69 cases]. Z Orthop Ihre Grenzgeb 127(4):392–395. https://doi.org/10.1055/s-2008-1044684CrossRefPubMed

42.

Jamshidi K, Sami S, Modares-Nejad HR, Jahansoz A (2008) Local recurrence in giant cell tumor of bone: comparative study of two methods of surgical approach. JRMS 13(5):223–229

43.

Rooney RJ, Asirvatham R, Lifeso RM et al (1993) Giant cell tumour of bone. A surgical approach to grade III tumours. Int Orthop 17(2):87–92. https://doi.org/10.1007/BF00183548CrossRefPubMed

44.

McDonald DJ, Sim FH, McLeod RA, Dahlin DC (1986) Giant-cell tumor of bone. J. Bone and Joini Surg 68-A:235–242CrossRef

45.

Zhen W, Yaotian H, Songjian L et al (2004) Giant-cell tumour of bone. The long-term results of treatment by curettage and bone graft. J Bone Joint Surg Br 86(2):212–216. https://doi.org/10.1302/0301-620x.86b2.14362CrossRefPubMed

46.

Abuhejleh H, Wunder JS, Ferguson PC et al (2020) Extended intralesional curettage preferred over resection-arthrodesis for giant cell tumour of the distal radius. Eur J Orthop Surg Traumatol 30(1):11–17. https://doi.org/10.1007/s00590-019-02496-2CrossRefPubMed

47.

Yip KM, Leung PC, Kumta SM (1996) Giant cell tumor of bone. Clin Orthop Relat Res 323:60–64. https://doi.org/10.1097/00003086-199602000-00008CrossRef

48.

Dürr HR, Maier M, Jansson V et al (1999) Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone. Eur J Surg Oncol 25(6):610–618. https://doi.org/10.1053/ejso.1999.0716CrossRefPubMed

49.

Malek F, Krueger P, Hatmi ZN et al (2006) Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy. Int Orthop 30(6):495–498. https://doi.org/10.1007/s00264-006-0146-3CrossRefPubMedPubMedCentral

50.

Suzuki Y, Nishida Y, Yamada Y et al (2007) Re-operation results in osteoarthritic change of knee joints in patients with giant cell tumor of bone. Knee 14(5):369–374. https://doi.org/10.1016/j.knee.2007.05.008CrossRefPubMed

51.

Deheshi BM, Jaffer SN, Griffin AM et al (2007) Joint salvage for pathologic fracture of giant cell tumor of the lower extremity. Clin Orthop Relat Res 459:96–104. https://doi.org/10.1097/BLO.0b013e31805d85e4CrossRefPubMed

52.

Morii T, Yabe H, Morioka H et al (2008) Curettage and allograft reconstruction for giant cell tumours. J Orthop Surg (Hong Kong) 16(1):75–79. https://doi.org/10.1177/230949900801600117CrossRef

53.

Abat F, Almenara M, Peiró A et al (2015) Tumor de células gigantes óseo. Noventa y siete casos con seguimiento medio de 12 años [Giant cell tumour of bone: a series of 97 cases with a mean follow-up of 12 years]. Rev Esp Cir Ortop Traumatol 59(1):59–65. https://doi.org/10.1016/j.recot.2014.06.005CrossRefPubMed

54.

Wada T, Kaya M, Nagoya S et al (2002) Complications associated with bone cementing for the treatment of giant cell tumors of bone. J Orthop Sci 7(2):194–198. https://doi.org/10.1007/s007760200033CrossRefPubMed

55.

Lewis VO, Wei A, Mendoza T et al (2006) Argon beam coagulation as an adjuvant for local control of giant cell tumor. Clinical Orthopaedics and Related Research 454:192–197. https://doi.org/10.1097/01.blo.0000238784.98606.d4CrossRef

56.

Fraquet N, Faizon G, Rosset P et al (2009) Long bones giant cells tumors: treatment by curettage and cavity filling cementation. Orthop Traumatol Surg Res 95(6):402–406. https://doi.org/10.1016/j.otsr.2009.07.004CrossRefPubMed

57.

Song Y, Li CF, Shi XT et al (2019) Zhongguo Gu Shang 32(4):372–376. https://doi.org/10.3969/j.issn.1003-0034.2019.04.016CrossRefPubMed

58.

Saikia KC, Bhattacharyya TD, Bhuyan SK et al (2011) Local recurrences after curettage and cementing in long bone giant cell tumor. Indian J Orthop 45(2):168–173. https://doi.org/10.4103/0019-5413.77138CrossRefPubMedPubMedCentral

59.

Xu HR, Niu XH, Zhang Q et al (2013) Subchondral bone grafting reduces degenerative change of knee joint in patients of giant cell tumor of bone. Chin Med J 126(16):3053–3056PubMed

60.

Shih HN, Hsu RW, Sim FH (1998) Excision curettage and allografting of giant cell tumor. World J Surg 22(5):432–437. https://doi.org/10.1007/s002689900411CrossRefPubMed

61.

Su YP, Chen WM, Chen TH (2004) Giant-cell tumors of bone: an analysis of 87 cases. Int Orthop 28(4):239–243. https://doi.org/10.1007/s00264-004-0564-zCrossRefPubMedPubMedCentral

62.

Ward WG Sr, Li G III (2002) Customized treatment algorithm for giant cell tumor of bone: report of a series. Clin Orthop Relat Res 397:259–270. https://doi.org/10.1097/00003086-200204000-00030CrossRef

63.

Saiz P, Virkus W, Piasecki P et al (2004) Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop Relat Res 424:221–226. https://doi.org/10.1097/01.blo.0000128280.59965.e3CrossRef

64.

Lackman RD, Hosalkar HS, Ogilvie CM et al (2005) Intralesional curettage for grades II and III giant cell tumors of bone. Clin Orthop Relat Res 438:123–127. https://doi.org/10.1097/01.blo.0000180051.27961.c3CrossRefPubMed

65.

Moon MS, Kim SS, Moon JL et al (2013) Treating giant cell tumours with curettage, electrocautery, burring, phenol irrigation, and cementation. J Orthop Surg (Hong Kong) 21(2):209–212. https://doi.org/10.1177/230949901302100219CrossRef

66.

Saibaba B, Chouhan DK, Kumar V et al (2014) Curettage and reconstruction by the sandwich technique for giant cell tumours around the knee. J Orthop Surg (Hong Kong) 22(3):351–355. https://doi.org/10.1177/230949901402200317CrossRef

67.

Wu M, Yao S, Xie Y et al (2018) A novel subchondral bone-grafting procedure for the treatment of giant-cell tumor around the knee: a retrospective study of 27 cases. Medicine (Baltimore) 97(45):e13154. https://doi.org/10.1097/MD.0000000000013154CrossRef

68.

Chawla S, Blay JY, Rutkowski P et al (2019) Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol 20(12):1719–1729. https://doi.org/10.1016/S1470-2045(19)30663-1CrossRefPubMed

69.

Urakawa H, Mizusawa J, Tanaka K et al (2019) A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan clinical oncology group study JCOG1610. Jpn J Clin Oncol 49(4):379–382. https://doi.org/10.1093/jjco/hyz004CrossRefPubMed

70.

Agarwal MG, Gundavda MK, Gupta R, Reddy R (2018) Does denosumab change the giant cell tumor treatment strategy? Lessons Learned From Early Experience. Clin Orthop Relat Res 476:1773–1782. https://doi.org/10.1007/s11999.0000000000000243CrossRefPubMedPubMedCentral

71.

Chinder PS, Hindiskere S, Doddarangappa S, Pal U (2019) Evaluation of local recurrence in giant-cell tumor of bone treated by Neoadjuvant Denosumab. Clinics in Orthopedic Surgery 11:352–360. https://doi.org/10.4055/cios.2019.11.3.352CrossRefPubMedPubMedCentral

72.

Puri A, Gulia A, Hegde P et al (2019) Neoadjuvant denosumab. Its role and results in operable cases of giant cell tumour of bone. Bone Joint J 101-B:170–177. https://doi.org/10.1302/0301-620X.101B2.BJJ-2018-0907CrossRefPubMed

73.

Tsukamoto S, Tanaka Y, Mavrogenis AF et al (2019) Is treatment with denosumab associated with local recurrence in patients with giant cell tumor of bone treated with curettage? A Systematic Review. Clin Orthop Relat Res:1–10. https://doi.org/10.1097/CORR.0000000000001074

74.

Chen X, Li H, Zhu S et al (2020) Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis. BMC Musculoskeletal Disorders 21:256. https://doi.org/10.1186/s12891-020-03294-2CrossRefPubMedPubMedCentral

Title: The impact of curettage technique on local control in giant cell tumour of bone
Authors: Gennady N. Machak
Andrey I. Snetkov
Publication date: 01-03-2021
Publisher: Springer Berlin Heidelberg
Keyword: Bone Tumor
Published in: International Orthopaedics / Issue 3/2021
Print ISSN: 0341-2695
Electronic ISSN: 1432-5195
DOI: https://doi.org/10.1007/s00264-020-04860-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The impact of curettage technique on local control in giant cell tumour of bone

Abstract

Introduction

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2021

The safety of outpatient total shoulder arthroplasty: a systematic review and meta-analysis

The blister occurring in severe tibial plateau fractures (Schatzker V–VI) decreases the risk of acute compartment syndrome

Letter to the editor regarding “Bone marrow lesion on magnetic resonance imaging indicates the last chance for hip osteonecrosis treated with vascularized fibular grafting before collapse”

Reply to the Letter to Editor by Aliyev et al.: Think about the distal femoral anatomy differences!

Managing patients’ expectations in orthopaedics

Comment on article by Pinsornsak Piya et al.: The effect of immediate post-operative knee range of motion photographs on post-operative range of motion after total knee arthroplasty: an assessor-blinded randomized controlled clinical trial in sixty patients